caa a22 4500 445316004 CHVBK 20180317142647.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1007/s10552-010-9694-3 doi (NATIONALLICENCE)springer-10.1007/s10552-010-9694-3 HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico [Elektronische Daten] [Yvonne Flores, David Bishai, Attila Lőrincz, Keerti Shah, Eduardo Lazcano-Ponce, Mauricio Hernández, Víctor Granados-García, Ruth Pérez, Jorge Salmerón] Objective: To determine the incremental costs and effects of different HPV testing strategies, when compared to Papanicolau cytology (Pap), for cervical cancer screening in Mexico. Methods: A cost-effectiveness analysis (CEA) examined the specific costs and health outcomes associated with (1) no screening; (2) only the Pap test; (3) only self-administered HPV; (4) only clinician administered HPV; and (5) clinician administered HPV plus the Pap test. The costs of self- and clinician-HPV testing, as well as with the Pap test, were identified and quantified. Costs were reported in 2008 US dollars. The health outcome associated with these screening strategies was defined as the number of high-grade cervical intraepithelial neoplasia or cervical cancer cases detected. This CEA was performed using the perspective of the Mexican Institute of Social Security (IMSS) in Morelos, Mexico. Results: Screening women between the ages of 30-80 for cervical cancer using clinical-HPV testing or the combination of clinical-HPV testing, and the Pap is always more cost-effective than using the Pap test alone. Conclusions: This CEA indicates that HPV testing could be a cost-effective screening alternative for a large health delivery organization such as IMSS. These results may help policy-makers implement HPV testing as part of the IMSS cervical cancer screening program. The Author(s), 2010 Cost-effectiveness nationallicence Cervical cancer nationallicence HPV nationallicence Screening nationallicence Mexico nationallicence Flores Yvonne Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Av. Plan de Ayala Esq. Central S/N, Cuernavaca, C.P. 62450, Morelos, México aut Bishai David Department of Population, Family, and Reproductive Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA aut Lőrincz Attila Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, Queen Mary University of London, London, UK aut Shah Keerti Department of Molecular Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA aut Lazcano-Ponce Eduardo Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México aut Hernández Mauricio Secretaria de Prevención y Promoción de la Salud, Secretaría de Salud, México D.F., México aut Granados-García Víctor Unidad de Investigación en Economía de la Salud, Instituto Mexicano del Seguro Social, 3er piso. Ed. de las Monjas. Av. Cuauhtemoc 330. Colonia Doctores, C.P. 06720, México D.F., México aut Pérez Ruth Departamento de Abastecimiento, Instituto Mexicano del Seguro Social, Hospital General Regional No. 1, Cuernavaca, Morelos, México aut Salmerón Jorge Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Av. Plan de Ayala Esq. Central S/N, Cuernavaca, C.P. 62450, Morelos, México aut Cancer Causes & Control Springer Netherlands 22/2(2011-02-01), 261-272 0957-5243 22:2<261 2011 22 10552 https://doi.org/10.1007/s10552-010-9694-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10552-010-9694-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Flores Yvonne Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Av. Plan de Ayala Esq. Central S/N, Cuernavaca, C.P. 62450, Morelos, México aut NATIONALLICENCE 700 1- Bishai David Department of Population, Family, and Reproductive Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA aut NATIONALLICENCE 700 1- Lőrincz Attila Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, Queen Mary University of London, London, UK aut NATIONALLICENCE 700 1- Shah Keerti Department of Molecular Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA aut NATIONALLICENCE 700 1- Lazcano-Ponce Eduardo Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México aut NATIONALLICENCE 700 1- Hernández Mauricio Secretaria de Prevención y Promoción de la Salud, Secretaría de Salud, México D.F., México aut NATIONALLICENCE 700 1- Granados-García Víctor Unidad de Investigación en Economía de la Salud, Instituto Mexicano del Seguro Social, 3er piso. Ed. de las Monjas. Av. Cuauhtemoc 330. Colonia Doctores, C.P. 06720, México D.F., México aut NATIONALLICENCE 700 1- Pérez Ruth Departamento de Abastecimiento, Instituto Mexicano del Seguro Social, Hospital General Regional No. 1, Cuernavaca, Morelos, México aut NATIONALLICENCE 700 1- Salmerón Jorge Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Av. Plan de Ayala Esq. Central S/N, Cuernavaca, C.P. 62450, Morelos, México aut NATIONALLICENCE 773 0- Cancer Causes & Control Springer Netherlands 22/2(2011-02-01), 261-272 0957-5243 22:2<261 2011 22 10552 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer